According to the Merger Market, the process of Mekong Capital selling its 25% stake worth US$52 million at Traphaco is in the last stages.
This is the amount of stock that Mekong Capital is trying to divest after ten years of operation. Traphaco’s shares are traded at the price of VND115,000 (roughly US$5) equal to the market capitalization of VND4,800 billion (roughly US$210.8 million).
Some pharmaceutical companies of South Korea such as Korean Korea Pharm and Shinpoong are finding chances to develop in Vietnam as this is a potential market.
Vietnam's pharmaceutical market value was about US$4.7 billion in 2016, 12 per cent higher than the previous year and is expected to increase to US$7 billion by 2020. Also, they have attracted the interest of partners thanks to the corporate tax incentives.
CVC Capital Partners, a global private equity and investment advisory firm, also joined the process to buy Mekong Capital stakes but has withdrawn recently.
